Dr Reddy's, Sun Pharma and Hetero lead the push as companies eye opportunities in Latin America, Africa and other emerging markets. For Indian pharmaceutical companies, overseas markets offer another avenue for growth, particularly in countries where semaglutide demand is already established and lower-priced alternatives could attract more patients. Don't miss the most important news and views of the day. Get them on our Telegram channel.